ABBOTT LABORATORIES | 2013 | FY | 3

Note 3 — Supplemental Financial Information

        Other (income) expense, net, for 2013 primarily relates to gains from the sales of equity securities. The loss on the extinguishment of debt of $1.35 billion in 2012 relates to the early redemption of $7.7 billion of long-term notes. The loss consists of the premium paid on the notes and the write off of deferred financing costs totaling $1.83 billion and was partially offset by a gain of $479 million related to the unwinding of interest rate swaps related to a portion of the debt. As discussed in Note 1, Other (income) expense, net, for 2011 includes a charge of $100 million to recognize the cumulative immaterial impacts to 2009 and 2010 relating to the change in year end for foreign subsidiaries.

        The detail of various balance sheet components is as follows:

 
   2013   2012  
 
   (in millions)
  

Long-term Investments:

              

Equity securities

   $ 93   $ 213  

Other

     26     61  
           
​ ​ ​ ​ ​ ​ ​ ​

Total

   $ 119   $ 274  
           
​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​
           

        The reduction in long-term investments from December 31, 2012 to December 31, 2013 is due primarily to the separation of AbbVie on January 1, 2013.

 
   2013   2012  
 
   (in millions)
  

Other Accrued Liabilities:

              

Accrued rebates payable to government agencies

   $ 136   $ 1,020  

Accrued other rebates (a)

     220     1,079  

All other (b)

     3,144     4,689  
           
​ ​ ​ ​ ​ ​ ​ ​

Total

   $ 3,500   $ 6,788  
           
​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​
           
(a)
Accrued wholesaler chargeback rebates of approximately $90 millon and $300 million at December 31, 2013 and 2012, respectively, are netted in trade receivables because Abbott's customers are invoiced at a higher catalog price but only remit to Abbott their contract price for the products. The reduction in the chargeback rebates from December 31, 2012 to December 31, 2013 is primarily due to the separation of AbbVie on January 1, 2013.

(b)
2013 and 2012 includes acquisition consideration payable of approximately $400 million related primarily to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business.

 
   2013   2012  
 
   (in millions)
  

Post-employment Obligations and Other Long-term Liabilities:

              

Defined benefit pension plans and post-employment medical and dental plans for significant plans

   $ 1,818   $ 4,871  

Deferred income taxes

     466     710  

All other (c)

     2,500     3,476  
           
​ ​ ​ ​ ​ ​ ​ ​

Total

   $ 4,784   $ 9,057  
           
​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​
           
(c)
2013 includes $1.3 billion of gross unrecognized tax benefits, as well as $70 million of acquisition consideration payable. 2012 includes $1.4 billion of gross unrecognized tax benefits, as well as acquisition consideration payable of $385 million related to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business.

us-gaap:AdditionalFinancialInformationDisclosureTextBlock